cis-4-(tert-butoxycarbonylamino)cyclohexanecarboxylic acid methyl ester | 364385-64-8

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cis-4-(tert-butoxycarbonylamino)cyclohexanecarboxylic acid methyl ester
• 英文别名: methyl trans-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate；(1s,4s)-methyl 4-((tert-butoxycarbonyl)amino)cyclohexanecarboxylate；methyl (1s,4s)-4-((tert-butoxycarbonyl)amino)cyclohexanecarboxylate；4-tert-butoxycarbonylaminocyclohexanecarboxylic acid methyl ester；methyl cis-4-((tert-butoxycarbonyl)amino)cyclohexanecarboxylate
• CAS: 364385-64-8
• 化学式: C₁₃H₂₃NO₄
• 分子量: 257.33
• InChiKey: RKOQMDUDKCMVFW-AOOOYVTPSA-N

物化性质

• 沸点：
  349.0±31.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.24
• 重原子数：
  18.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  64.63
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  cis-4-(tert-butoxycarbonylamino)cyclohexanecarboxylic acid methyl ester 以 乙醚 为溶剂， 生成 cis-N-(tert-butoxycarbonyl)-4-hydroxymethylcyclohexylamine
  参考文献：
  名称：

  Heterocycle derivatives and drugs

  摘要：

  提供了一种出色的新型镇痛药，具有对疼痛产生镇痛作用的效果，广泛对抗各种疼痛，包括慢性疼痛或伴随带状疱疹的痛觉过敏，通过作用于一种痛觉素受体。本发明涉及以下式表示的化合物或其盐。在该式中，X和Y相同或不同，每个代表一个氮原子或CH；R1代表一个氢原子或烷基等；A1和A2相同或不同，每个代表一个单键或双价脂肪烃基；Q代表一个单键，环烷基，苯基或双价杂环基；R2A，R2B，R2C和R2D相同或不同，每个代表一个氢原子，烷基或苯基；E代表一个乙烯基或—NRCO—（其中R为氢或烷基）等；R3代表一个苯基或杂环基；R4和R5相同或不同，每个代表一个氢原子，烷基，烷氧基，芳基氧基，卤素，硝基，羟基，烷氧羰基，—NR6R7（其中R6和R7相同或不同，每个代表一个氢原子或烷基）等。

  公开号：

  US20030119855A1
• 作为产物：
  描述：

  cis-4-amino-cyclohexanecarboxylic acid hydrochloride 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 cis-4-(tert-butoxycarbonylamino)cyclohexanecarboxylic acid methyl ester
  参考文献：
  名称：

  D₂ Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine

  摘要：

  Functionally selective G protein-coupled receptor ligands are valuable tools for deciphering the roles of downstream signaling pathways that potentially contribute to therapeutic effects versus side effects. Recently, we discovered both G(i/o)-biased and beta-arrestin2-biased D-2 receptor agonists based on the Food and Drug Administration (FDA)-approved drug aripiprazole. In this work, based on another FDA-approved drug, cariprazine, we conducted a structure-functional selectivity relationship study and discovered compound 38 (MS1768) as a potent partial agonist that selectively activates the G(i/o) pathway over beta-arrestin2. Unlike the dual D2R/D3R partial agonist cariprazine, compound 38 showed selective agonist activity for D2R over D3R. In fact, compound 38 exhibited potent antagonism of dopamine-stimulated beta-arrestin2 recruitment. In our docking studies, compound 38 directly interacts with S193(5.42) on TM5 but has no interactions with extracellular loop 2, which appears to be in contrast to the binding poses of D2R beta-arrestin2-biased ligands. In in vivo studies, compound 38 showed high D2R receptor occupancy in mice and effectively inhibited phencyclidine-induced hyperlocomotion.

  DOI：

  10.1021/acs.jmedchem.9b00508

文献信息

• [EN] IRAK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION D'IRAK ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020264499A1

  公开（公告）日：2020-12-30

  The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。这些化合物包括能够结合到IRAK4的IRAK结合基团和诱导降解的基团（DIM）。DIM可以是DTM、一个连接酶结合基团（LBM）或赖氨酸类似物。这些化合物可以作为IRAK蛋白激酶抑制剂，并应用于IRAK介导的疾病。
• Copper-Catalyzed and Indium-Mediated Methoxycarbonylation of Unactivated Alkyl Iodides with Balloon CO
  作者：Yanchi Chen、Lei Su、Hegui Gong

  DOI：10.1021/acs.orglett.9b01573

  日期：2019.6.21

  This work emphasizes the synthesis of alkyl esters via Cu-catalyzed and In-mediated alkoxycarbonylation of unactivated alkyl iodides in the presence of In or InI. The reactions were suitable for the preparation of primary, secondary, and even tertiary alkyl esters, representing an exceptionally rare example for the creation of quaternary carbon centers upon formation of esters. The preliminary mechanistic

  这项工作强调在In或InI的存在下，通过Cu催化和In介导的未活化烷基碘的烷氧基羰基化来合成烷基酯。该反应适合于伯，仲，甚至叔烷基酯的制备，代表了在形成酯时生成季碳中心的极为罕见的例子。初步的机理研究表明，涉及烷基自由基，而Cu / In / CO在羰基化事件中起着协同作用。
• Diamine derivatives as factor X inhibitors
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2343290A1

  公开（公告）日：2011-07-13

  The invention relates to a compound represented by the general formula (1):         Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4     (1) the salt thereof, the solvate thereof, or N-oxide thereof, wherein R1, R2; Q1 Q2, Q3, Q4, T° and T1 are as defined in claim 1. The compound inhibits activated blood coagulation factor X ("FXa") to exhibit a potent anticoagulant effect and can be orally administered. The compound is useful as an agent for preventing and/or treating thrombosis or embolism and as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood gathering.

  本发明涉及一种由通式（1）表示的化合物：Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1），其盐，溶剂化物或N-氧化物，其中R1，R2；Q1，Q2，Q3，Q4，T°和T1如权利要求书所定义。该化合物抑制活化的血凝血因子X（“FXa”），展现出强效的抗凝作用，并可口服。该化合物可用作预防和/或治疗血栓形成或栓塞的药剂，以及用于预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固。
• Vla-4 inhibitors
  申请人：——

  公开号：US20040110945A1

  公开（公告）日：2004-06-10

  The present invention relates to a compound represented by the following formula (I): 1 (wherein, W represents W A —A 1 —W B — (in which, W A is substituted or unsubstituted aryl, etc., A 1 is —NR 1 —, single bond, —C(O)—, etc., and W B is substituted or unsubstituted arylene, etc.), R is single bond, —NH—, —OCH 2 —, alkenylene, etc., X is —C(O)—, —CH 2 —, etc., and M is, for example, the following formula: 2 (in which, R 11 , R 12 and R 13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R 14 is hydrogen or lower alkyl, Y represents —CH 2 —O—, etc., Z is substituted or unsubstituted arylene, etc., A 2 is single bond, etc, and R 10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.

  本发明涉及以下式(I)所表示的化合物：1（其中，W代表WA-A1-WB-（其中，WA是取代或未取代的芳基等，A1是-NR1-，单键，-C（O）-等，WB是取代或未取代的芳烃基等），R是单键，-NH-，-O -，烯烃基等，X是-C（O）-，-CH2-等，M是例如以下公式：2（其中，R11，R12和R13分别独立地代表氢，羟基，氨基，卤素等，R14是氢或低级烷基，Y代表- -O-等，Z是取代或未取代的芳烃基等，A2是单键等，而R10是羟基或低级烷氧基），或其盐；以及含有该化合物的药物。该化合物或其盐选择性地抑制细胞黏附分子与VAL-4的结合，并表现出高的生物利用度，因此可用作预防和/或治疗炎症性疾病、自身免疫性疾病、转移、支气管哮喘、鼻窦狭窄、糖尿病等。
• Quinazoline derivatives and drugs
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：US06794389B2

  公开（公告）日：2004-09-21

  There is provided an excellent novel analgesic having an analgesic effect which is effective widely against a pain including a chronic pain or an allodynia accompanied with herpes zoster by acting on a nociceptin receptor. The present invention relates to a compound represented by the following formula: or a salt thereof. In the formula, X and Y are same or different and each represents a nitrogen atom or CH; R1 represents a hydrogen atom or alkyl and the like; A1 and A2 are same or different and each represents a single bond or a divalent aliphatic hydrocarbon group; Q represents a single bond, cycloalkylene group, phenylene group or divalent heterocyclic group; R2A, R2B, R2C and R2D are same or different and each represents a hydrogen atom, alkyl or phenyl; E represents a ethenylene group or —NRCO— (in which R is hydrogen or alkyl) and the like; R3 represents a phenyl group or a heterocyclic group; R4 and R5 are same or different and each represents a hydrogen atom, alkyl, alkoxy, aralkyloxy, halogen, nitro, hydroxy, alkoxycarbonyl, —NR6R7 (in which R6 and R7 are same or different and each represents a hydrogen atom or alkyl) and the like.

  提供了一种出色的新型止痛剂，具有广泛的止痛效果，可用于治疗包括带状疱疹伴随的慢性疼痛或痛觉过敏等疼痛。该止痛剂通过作用于nociceptin受体来发挥作用。本发明涉及以下公式所表示的化合物或其盐。在该公式中，X和Y相同或不同，每个代表氮原子或CH; R1代表氢原子或烷基等; A1和A2相同或不同，每个代表单键或二价脂肪烃基; Q代表单键，环烷基，苯基或二价杂环基; R2A，R2B，R2C和R2D相同或不同，每个代表氢原子，烷基或苯基; E代表乙烯基或—NRCO—（其中R为氢或烷基）等; R3代表苯基或杂环基; R4和R5相同或不同，每个代表氢原子，烷基，烷氧基，芳基烷氧基，卤素，硝基，羟基，烷氧羰基，—NR6R7（其中R6和R7相同或不同，每个代表氢原子或烷基）等。